Kintara Therapeutics Inc

NASDAQ:KTRAUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC), basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients. VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly diagnosed methylated MGMT; newly diagnosed unmethylated MGMT, and recurrent.

Contact Information

Headquarters

9920 Pacific Heights Blvd Suite 150, Suite 200SAN DIEGO, CA, United States 92121

Phone

858-350-4364

Fax

604-202-1384

Executives

Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer

Robert Hoffman

Senior Vice President, Business Development

John Liatos

Independent Director

Laura Johnson

Independent Director

Tamara Seymour

Independent Director

Robert Toth